1
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
Condition(s):Chronic Hepatitis CLast Updated:March 7, 2017Not yet recruiting
Daclatasvir and Asunaprevir: 45 Clinical Trials, Page 1 of 5
Hide Studies Not Open or Pending
2
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Condition(s):Hepatitis CLast Updated:April 19, 2017Completed
3
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Condition(s):Hepatitis CLast Updated:July 18, 2018Completed
4
A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
Condition(s):Hepatitis C InfectionLast Updated:February 24, 2015Completed
5
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
Condition(s):Hepatitis CLast Updated:January 21, 2022Completed
6
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
Condition(s):Hepatitis cLast Updated:April 19, 2018Withdrawn
7
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
Condition(s):Hepatitis CLast Updated:January 9, 2019Completed
8
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
Condition(s):HIV-HCVLast Updated:May 16, 2017Completed
9
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Condition(s):Hepatitis CLast Updated:August 11, 2020Completed
10
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C
Condition(s):Hepatitis C, ChronicLast Updated:December 28, 2015Unknown status